COPN Stock Overview
Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Cosmo Pharmaceuticals N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 47.45 |
| 52 Week High | CHF 80.60 |
| 52 Week Low | CHF 44.95 |
| Beta | 1.38 |
| 1 Month Change | -14.20% |
| 3 Month Change | -25.63% |
| 1 Year Change | -33.36% |
| 3 Year Change | -18.47% |
| 5 Year Change | -37.15% |
| Change since IPO | 112.78% |
Recent News & Updates
Recent updates
Clascoterone Trials Completion And AI Expansion Will Open Future Markets
Mar 17 Strong cash position and no debt provide flexibility for strategic investments, boosting future profitability and earnings.Weekly Picks: NLBR’s vision, MNSO’s expansion plans and COPN’s opportunity
Jan 23
Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
Jan 20Revenue: €265.7 million, representing a 186% year-over-year increase from €92.8 million in 2023. This includes €185 million in non-recurring revenues from Medtronic linked to the December 2023 expandeCosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable
Nov 22Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues
May 02Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture
Mar 28Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher
Mar 26Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear
Dec 01Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jul 29We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt
Nov 24Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals
Mar 31Shareholder Returns
| COPN | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 1.8% | 8.4% | 6.2% |
| 1Y | -33.4% | 11.6% | 1.2% |
Return vs Industry: COPN underperformed the Swiss Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: COPN underperformed the Swiss Market which returned 1.2% over the past year.
Price Volatility
| COPN volatility | |
|---|---|
| COPN Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in CH Market | 8.6% |
| 10% least volatile stocks in CH Market | 2.4% |
Stable Share Price: COPN's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: COPN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 322 | Giovanni Di Napoli | www.cosmopharma.com |
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin 1% enema that is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis; Colesevelam, which is in preclinical studies for the treatment of bile acid diarrhea; and Cortexolone 17a-valerate-21-propionate, an oral Androgen receptor and glucocorticoid receptor antagonist that is in Phase I clinical trial for treatment solid tumors, as well as provides Cosmo’s AI technology, a GI Genius intelligent endoscopy system.
Cosmo Pharmaceuticals N.V. Fundamentals Summary
| COPN fundamental statistics | |
|---|---|
| Market cap | CHF 763.92m |
| Earnings (TTM) | CHF 123.75m |
| Revenue (TTM) | CHF 247.78m |
6.1x
P/E Ratio3.1x
P/S RatioIs COPN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COPN income statement (TTM) | |
|---|---|
| Revenue | €266.79m |
| Cost of Revenue | €45.36m |
| Gross Profit | €221.43m |
| Other Expenses | €88.19m |
| Earnings | €133.24m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Jul 23, 2025
| Earnings per share (EPS) | 8.32 |
| Gross Margin | 83.00% |
| Net Profit Margin | 49.94% |
| Debt/Equity Ratio | 0.08% |
How did COPN perform over the long term?
See historical performance and comparisonDividends
4.0%
Current Dividend Yield25%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/17 18:37 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cosmo Pharmaceuticals N.V. is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Pfeifer-Rossi | Bank am Bellevue |
| Silvia Schanz | Bank Vontobel AG |
| Laura Hindley | Berenberg |